752 results on '"van Hoek, Bart"'
Search Results
2. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial
3. OS-120 Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
4. Nutritional assessment in patients with chronic liver disease – Current accessibility and implementation
5. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
6. Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework
7. Incidence and prevalence of primary biliary cholangitis in the Netherlands – A nationwide cohort study
8. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
9. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis
10. Bacterial Infections After Liver Transplantation and the Role of Oral Selective Digestive Decontamination: A Retrospective Cohort Study
11. Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)
12. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis
13. Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial
14. Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma
15. Prevalence of non-alcoholic fatty liver in the general Dutch population and in groups at increased risk
16. Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation
17. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group
18. Skeletal muscle mass in patients with end-stage liver disease: Not only muscle size but especially muscle quality matters in relation to physical fitness
19. Intraductal fully covered self-expandable metal stent versus multiple plastic stents for treating biliary anastomotic strictures after liver transplantation
20. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis
21. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation
22. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis
23. Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study
24. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation
25. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial
26. WED-182 The enhanced liver fibrosis test in alpha-1 antitrypsin deficiency patients homozygous for the Z-allele
27. THU-138 The male-to-female ratio among patients with primary biliary cholangitis depends on age
28. OS-015 Time to complete biochemical response and disease progression in autoimmune hepatitis
29. FRI-043 A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial
30. Incidence and prevalence of primary biliary cholangitis in the Netherlands – a nationwide cohort study
31. WED-135-YI Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)
32. THU-100 Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis
33. TOP-141 Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management
34. THU-120-YI The impact of ursodeoxycholic acid on biochemistry of patients with primary biliary cholangitis in a nationwide cohort
35. WED-179-YI Liver fibrosis status and circulating polymers in alpha-1 antitrypsin deficiency patients with a Z/rare genotype
36. SAT-021 Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort
37. Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure
38. Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome
39. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region
40. Donor hepatectomy time influences ischemia-reperfusion injury of the biliary tree in donation after circulatory death liver transplantation
41. The role of complement activation in autoimmune liver disease
42. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months
43. Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?
44. Prednisolone with azathioprine or mycophenolate mofetil as first-line therapy in autoimmune hepatitis: insights from a randomized controlled trial
45. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
46. Reply to: “Challenges in the diagnosis and management of AIH-PBC syndrome”
47. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial
48. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
49. Incidence and prevalence of primary biliary cholangitis in the Netherlands – A nationwide cohort study
50. Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus:A Multicenter, Randomized Controlled Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.